Gratus Capital’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | $4.29M | Buy |
4,741
+351
| +8% | +$281K | 0.17% | 105 |
|
|
2024
Q1 | $3.42M | Buy |
4,390
+1,305
| +42% | +$929K | 0.16% | 106 |
|
|
2023
Q4 | $1.8M | Sell |
3,085
-201
| -6% | -$117K | 0.1% | 122 |
|
|
2023
Q3 | $1.76M | Buy |
3,286
+237
| +8% | +$122K | 0.12% | 113 |
|
|
2023
Q2 | $1.43M | Sell |
3,049
-100
| -3% | -$41.9K | 0.1% | 116 |
|
|
2023
Q1 | $1.08M | Sell |
3,149
-1,814
| -37% | -$612K | 0.08% | 121 |
|
|
2022
Q4 | $1.82M | Buy |
4,963
+70
| +1% | +$24.8K | 0.15% | 96 |
|
|
2022
Q3 | $1.58M | Buy |
4,893
+108
| +2% | +$34.2K | 0.17% | 96 |
|
|
2022
Q2 | $1.55M | Buy |
4,785
+9
| +0.2% | +$2.7K | 0.17% | 89 |
|
|
2022
Q1 | $1.37M | Buy |
4,776
+10
| +0.2% | +$2.57K | 0.13% | 100 |
|
|
2021
Q4 | $1.32M | Buy |
4,766
+109
| +2% | +$27.6K | 0.12% | 103 |
|
|
2021
Q3 | $1.08M | Buy |
4,657
+353
| +8% | +$87.1K | 0.12% | 102 |
|
|
2021
Q2 | $988K | Buy |
4,304
+10
| +0.2% | +$2.01K | 0.11% | 104 |
|
|
2021
Q1 | $802K | Sell |
4,294
-226
| -5% | -$44.2K | 0.1% | 119 |
|
|
2020
Q4 | $763K | Buy |
4,520
+249
| +6% | +$37.2K | 0.1% | 114 |
|
|
2020
Q3 | $632K | Sell |
4,271
-749
| -15% | -$116K | 0.1% | 116 |
|
|
2020
Q2 | $824K | Buy |
5,020
+13
| +0.3% | +$2K | 0.14% | 108 |
|
|
2020
Q1 | $695K | Buy |
5,007
+6
| +0.1% | +$824 | 0.13% | 115 |
|
|
2019
Q4 | $657K | Sell |
5,001
-39
| -0.8% | -$4.52K | 0.1% | 118 |
|
|
2019
Q3 | $564K | Buy |
5,040
+16
| +0.3% | +$1.78K | 0.09% | 123 |
|
|
2019
Q2 | $557K | Buy |
5,024
+14
| +0.3% | +$1.65K | 0.09% | 123 |
|
|
2019
Q1 | $650K | Buy |
5,010
+303
| +6% | +$36.8K | 0.11% | 120 |
|
|
2018
Q4 | $545K | Buy |
4,707
+13
| +0.3% | +$1.45K | 0.11% | 126 |
|
|
2018
Q3 | $504K | Buy |
4,694
+294
| +7% | +$29.4K | 0.07% | 132 |
|
|
2018
Q2 | $375K | Buy |
4,400
+18
| +0.4% | +$1.48K | 0.06% | 136 |
|
|
2018
Q1 | $339K | Buy |
+4,382
| New | +$353K | 0.05% | 150 |
|
|
2016
Q2 | – | Sell |
-4,242
| Closed | -$305K | – | 181 |
|
|
2016
Q1 | $305K | Buy |
4,242
+18
| +0.4% | +$1.36K | 0.07% | 54 |
|
|
2015
Q4 | $356K | Hold |
4,224
| – | – | 0.08% | 71 |
|
|
2015
Q3 | $354K | Sell |
4,224
-1,200
| -22% | -$101K | 0.09% | 76 |
|
|
2015
Q2 | $453K | Hold |
5,424
| – | – | 0.11% | 72 |
|
|
2015
Q1 | $394K | Buy |
+5,424
| New | +$386K | 0.09% | 76 |
|
Other funds holding LLY
Gratus Capital's LLY Position: Q2 2024 in Review
Gratus Capital increased its Eli Lilly (LLY) stake by 8% in Q2 2024, buying an estimated $281K and bringing the position to 4,741 shares worth $4.29M. The position accounts for 0.17% of the portfolio, ranked #105.
Gratus Capital first reported a position in LLY in Q1 2015 and has held it in 31 quarters since. 3,564 funds tracked by Wall St. Rank hold LLY as of Q2 2024.
- Gratus Capital held 4,741 shares of Eli Lilly worth $4.29M as of Q2 2024.
- Gratus Capital bought 351 Eli Lilly shares in Q2 2024, an estimated $281K.
- Eli Lilly made up 0.17% of Gratus Capital's portfolio in Q2 2024, its #105 holding.
- Gratus Capital first reported a position in Eli Lilly in Q1 2015 and has held it in 31 quarters since.
- 3,564 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2024.
Based on Gratus Capital's 13F filing for Q2 2024, filed 25 Jul 2024.